Menu
Recruiting NCT06728436

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

No phase Interventional Alzheimer Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CuidaTEXT.
Who it may be relevant to
Registry conditions: Alzheimer Disease. Basic parameters: 18 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences . Participants will receive a variety of text messages, from automatic to keyword-drive, regarding ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.

Interventions

  • Behavioral CuidaTEXT
    CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.

Primary outcome measures

  • Change in caregiver depressive symptoms [Time frame: Baseline and 6 months]
Secondary outcome measures (1)
  • Change in caregiver behavioral distress symptoms [Time frame: Baseline and 6 months]

Eligibility criteria

Inclusion criteria

  • Over the age of 18
  • Spanish and English-speaking people who identify as Latino
  • Reports providing hands-on care for a relative who has been given a clinical or research ADRD diagnosis and has an Eight-item Informant Interview to Differentiate Aging and Dementia (AD-8) screening score ≥2, indicating cognitive impairment
  • Has a score of 7 or higher on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10)
  • Self-reports being able to read and write
  • Owns a cell phone with a flat fee, and uses it at least weekly for texting.

Exclusion criteria

  • Participation in another wellbeing-related clinical trial
  • Cohabitation with another participant in the CuidaTEXT R01 Study
  • Participants who provide care for a person with ADRD already cared for by another participant in the CuidaTEXT R01 study
  • Participant plans to move to another country within seven months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • University of Kansas Medical Center — Fairway

Publications

  • Perales-Puchalt J, Ramirez-Mantilla M, Moore HP, Velez-Uribe I, Sepulveda-Rivera V, Ruiz R, Fracachan-Cabrera M, Herrera Y, Baker C, Miras-Neira A, Bothwell B, Anderson H, Lewandowski T, Diaz FJ, Greiner KA, Williams K, Vidoni ED, Ellerbeck E, Burns JM. Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: a randomized controlled trial prot PMID 41001476

Identifiers

NCT: NCT06728436 · 150585 · 1R01AG082306

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗